Back
Compare AU
Compare ACDC vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X Battery Tech & Lithium ETF (ACDC) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
ACDC | CURE | |
|---|---|---|
Popularity | Medium | Low |
Pearlers invested | 2,282 | 73 |
Median incremental investment | $800.00 | $660.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,200.16 | $1,734.78 |
Average age group | > 35 | > 35 |
Key Summary
ACDC | CURE | |
|---|---|---|
Strategy | The Global X Battery Tech & Lithium ETF (ASX: ACDC) seeks to track the performance of The Solactive Global Lithium Index before account fees, expenses and taxes. The index invests in companies involved in the lithium business. This includes companies involved in all aspects of lithium, from mining and refining the metal, to producing batteries and Electric Vehicles (EVs). | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | SolarEdge Technologies Inc (5.39 %) Eos Energy Enterprises Inc Ordinary Shares Class A (5.38 %) Canadian Solar Inc (4.95 %) | Avidity Biosciences Inc Ordinary Shares (2.45 %) Revolution Medicines Inc Ordinary Shares (2.36 %) Insmed Inc (2.14 %) |
Top 3 industries | Materials (38.52 %) Industrials (27.84 %) Information Technology (23.72 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | Japan (23.82 %) United States (18.30 %) Korea (13.38 %) | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) |
Management fee | 0.69 % | 0.45 % |
Key Summary
ACDC | CURE | |
|---|---|---|
Issuer | Global X | Global X |
Tracking index | Solactive Battery Value-Chain Index | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.69 % | 0.45 % |
Price | $137.51 | $59.82 |
Size | $663.763 million | $38.099 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 4.02 % | 5.08 % |
Market | ASX | ASX |
First listed date | 03/09/2018 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
ACDC | CURE | |
|---|---|---|
Popularity | Medium | Low |
Pearlers invested | 2,282 | 73 |
Median incremental investment | $800.00 | $660.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,200.16 | $1,734.78 |
Average age group | > 35 | > 35 |
Pros and Cons
ACDC | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
ACDC | CURE |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |